PROVECTUS BIOPHARMACEUTICALS, INC. Quarterly Debt-to-equity in % from Q1 2012 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Provectus Biopharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q1 2012 to Q2 2024.
  • Provectus Biopharmaceuticals, Inc. Debt-to-equity for the quarter ending June 30, 2024 was -117 %, a 8.24% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 -117 +10.5 +8.24% Jun 30, 2024
Q1 2024 -120 +11.7 +8.89% Mar 31, 2024
Q4 2023 -122 Dec 31, 2023
Q3 2023 -125 Sep 30, 2023
Q2 2023 -127 Jun 30, 2023
Q1 2023 -131 Mar 31, 2023
Q4 2021 -113 -8.85 -8.5% Dec 31, 2021
Q3 2021 -104 +1.56 +1.48% Sep 30, 2021
Q2 2021 -103 +2.29 +2.17% Jun 30, 2021
Q1 2021 -104 +3.19 +2.98% Mar 31, 2021
Q4 2020 -104 +6.84 +6.17% Dec 31, 2020
Q3 2020 -105 +7.32 +6.51% Sep 30, 2020
Q2 2020 -106 +9.23 +8.03% Jun 30, 2020
Q1 2020 -107 +10.8 +9.17% Mar 31, 2020
Q4 2019 -111 +7.73 +6.51% Dec 31, 2019
Q3 2019 -112 +11.7 +9.4% Sep 30, 2019
Q2 2019 -115 +16.9 +12.8% Jun 30, 2019
Q1 2019 -118 +27 +18.7% Mar 31, 2019
Q4 2018 -119 Dec 31, 2018
Q3 2018 -124 Sep 30, 2018
Q2 2018 -132 Jun 30, 2018
Q1 2018 -145 Mar 31, 2018
Q4 2015 8.91 -5.6 -38.6% Dec 31, 2015
Q3 2015 5.06 -34.3 -87.1% Sep 30, 2015
Q2 2015 5.35 -46.5 -89.7% Jun 30, 2015
Q1 2015 7.29 -66.5 -90.1% Mar 31, 2015
Q4 2014 14.5 -74.9 -83.8% Dec 31, 2014
Q3 2014 39.4 -11.6 -22.8% Sep 30, 2014
Q2 2014 51.8 -10.6 -16.9% Jun 30, 2014
Q1 2014 73.8 -2.35 -3.09% Mar 31, 2014
Q4 2013 89.4 +13.9 +18.3% Dec 31, 2013
Q3 2013 51 -13.4 -20.8% Sep 30, 2013
Q2 2013 62.4 +12.2 +24.2% Jun 30, 2013
Q1 2013 76.2 +35 +84.8% Mar 31, 2013
Q4 2012 75.6 Dec 31, 2012
Q3 2012 64.4 Sep 30, 2012
Q2 2012 50.2 Jun 30, 2012
Q1 2012 41.2 Mar 31, 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.